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Abstract
Background: Few data exist on survival or health-related quality of life (QOL) related to herbal remedy use among
long-term breast cancer survivors. The objective of this report is to examine whether herbal remedy use is
associated with survival or the health-related QOL of these long-term breast cancer survivors.
Methods: In 1999-2000, we collected the information of herbal remedy use and QOL during a telephone interview
with 371 Los Angeles Non-Hispanic/Hispanic white women who had survived more than 10 years after breast cancer
diagnosis. QOL was measured using the Medical Outcomes Study Short Form-36 (SF-36) questionnaire. Patients were
followed for mortality from the baseline interview through 2007. 299 surviving patients completed a second
telephone interview on QOL in 2002-2004. We used multivariable Cox proportional hazards methods to estimate
relative risks (RR) and 95% confidence intervals (CI) for mortality and applied multivariable linear regression models to
compare average SF-36 change scores (follow-up - baseline) between herbal remedy users and non-users.
Results: Fifty-nine percent of participants were herbal remedy users at baseline. The most commonly used herbal
remedies were echinacea, herbal teas, and ginko biloba. Herbal remedy use was associated with non-statistically
significant increases in the risks for all-cause (44 deaths, RR = 1.28, 95% CI = 0.62-2.64) and breast cancer (33
deaths, RR = 1.78, 95% CI = 0.72-4.40) mortality. Both herbal remedy users’ and non-users’ mental component
summary scores on the SF-36 increased similarly from the first survey to the second survey (P = 0.16), but herbal
remedy users’ physical component summary scores decreased more than those of non-users (-5.7 vs. -3.2, P = 0.02).
Conclusions: Our data provide some evidence that herbal remedy use is associated with poorer survival and a
poorer physical component score for health-related QOL among women who have survived breast cancer for at
least 10 years. These conclusions are based on exploratory analyses of data from a prospective study using two-
sided statistical tests with no correction for multiple testing and are limited by few deaths for mortality analysis
and lack of information on when herbal remedy use was initiated or duration of or reasons for use.
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Background
While the use of complementary and alternative medi-
cine (CAM, including herbal remedies), has increased
among the general population [1]. CAM use still
remains more common among cancer patients [2].
Among cancer patients, breast cancer patients remain as
the most likely users of CAM [3]. The prevalence of
CAM among cancer patients varies based on different
CAM definitions [4,5]. Richardson et al. reported that as
many as 83% breast cancer patients use at least one type
of CAM [6]. The leading reasons why breast cancer
patients use CAM include improving their quality of life
(QOL), aiding their conventional medical treatment for
cancers, preventing their cancer recurrence, and even-
tually extending their lifespan [7,8]. However, few scien-
t i f i cd a t ae x i s to ns u r v i v al or QOL in relation to CAM
use, especially herbal remedy use, among long-term
breast cancer survivors.
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and cancer patients’ survival has rarely been studied.
One Norwegian study following 252 patients with a mix
of different cancers for 5 years reported that CAM use
had no impact on mortality [9]. Another Norwegian
study following 515 patients with different types of can-
cer for 8 years found that CAM users had a 30% higher
mortality risk (P = 0.056) during the follow-up period
than non-CAM users [10]. Neither study provided data
specifically for breast cancer patients.
Most previous studies that evaluated CAM or herbal
remedy use by patients in relation to QOL were con-
ducted within 5 years of their initial diagnosis [11-14].
Recently, long-term breast cancer survivors’ QOL has
started to attract attention from researchers [15-17].
Such research is needed, especially given that early
detection and efficacious adjuvant systemic therapy of
breast cancer have improved the likelihood of long-term
survival. Based on the data from the National Cancer
Institute’s Surveillance, Epidemiology, and End Results
(SEER) Program, the proportion of patients with stage I
(T1a,bN0M0) breast cancer diagnosed between 1988
and 2001 who remain alive at 10 years post-diagnosis is
76% [18]. Younger women who become long-term survi-
vors commonly experience late health effects of treat-
ment, symptoms associated with a deficit of estrogen,
fear of recurrence, problems with sexuality, and poorer
mental health and psychologic distress [15,17]. In a sur-
vey on beliefs about the roles of CAM use conducted
among long-term breast cancer survivors (on average,
8.7 year post-diagnosis), more than 50% believed that
CAM use would prevent cancer recurrence (69%), play a
more active role in recovery (67%), and help to manage
stress (64%) [19] although thus far, few scientific data
exist to support these beliefs.
We previously reported that, among women who were
long-term (> 10 years) breast cancer survivors and aged
40 years or younger when initially diagnosed, herbal
remedy users had a lower mental component summary
score on the Medical Outcomes Study Short Form-36
(SF-36) questionnaire than non-users, but herbal remedy
users and non-users did not differ on the SF-36 physical
component summary scores [20]. In our previous report,
QOL and herbal remedy use information were collected
at the same point in time and we were thus not able to
determine whether herbal remedy use is associated with
later QOL. However, additional follow-up data on these
patients’ QOL collected 2-5 years after the initial collec-
tion of herbal information now affords us the opportu-
nity to evaluate whether herbal remedy use at baseline
is associated with the changes in SF-36 QOL measures
between the two surveys. Furthermore, the extended fol-
low-up data on women’s survival from baseline (1999-
2000) through 2007 provides the opportunity to explore
whether herbal remedy use at baseline is associated with
mortality among long-term breast cancer survivors. In
this report, we examined whether herbal remedy use is
associated with survival or the health-related QOL of
these long-term breast cancer survivors.
Methods
Study population
Participants were breast cancer patients enrolled in a
Los Angeles County population-based epidemiologic
case-control study of breast cancer among Non-Hispa-
nic/Hispanic white women who were 40 years or
younger at diagnosis (referred to as the “parent study”).
Details of the parent study have been published [21].
Briefly, white female residents of Los Angeles County
diagnosed with first primary in situ or invasive breast
cancer between July 1, 1983, and January 1, 1989, who
were 40 years of age or younger at diagnosis, and who
were born in the United States, Canada, or Europe, were
eligible for participation in the parent study. Nine hun-
dred and sixty nine eligible breast cancer patients were
identified by the Los Angeles County Cancer Surveil-
lance Program (LA-CSP), a population-based SEER reg-
istry. Of the 969 eligible women with incident breast
cancer, 225 were not interviewed for the following rea-
sons: death (n = 20), physician refusal (n = 54), serious
mental or physical illness (n = 7), patient refusal (n =
111), no longer living in Los Angeles County (n = 12),
and inability to be located (n = 21). Interviews were
completed with 744 breast cancer patients (in situ:n=
68, invasive: n = 676).
The 744 participants were traced in 1998 and inter-
viewed in 1999 and 2000 by telephone to collect the
detailed information regarding herbal remedy use and
concurrent QOL. Of the 744 women, 276 were known
t oh a v ed i e db yt h et i m et h eb a s e l i n et e l e p h o n ei n t e r -
view for herbal remedy use was initiated; 78 women
were not located; 6 subjects refused participation; and
10 women were interested but unable to schedule an
interview during the study period. Three hundred
seventy-four women were interviewed. The interviews
were conducted, on average, 13 years after diagnosis.
The cross-sectional relationship between herbal remedy
use and QOL has been reported elsewhere [20].
The 374 women who participated in our baseline tele-
phone interview for herbal remedy use were followed
for survival through December 31, 2007 by linking with
the LA-CSP and the National Death Index. If death
occurred, information on date of death and cause of
death was collected. Person-days of follow-up for each
woman began on the date of baseline telephone inter-
view and ended on her date of death (n = 44 including
33 who died of breast cancer) or December 31, 2007
(n = 330). Among 33 who died from breast cancer, 13
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breast cancer; 2 had a contralateral breast cancer; 10
had a combination of these three conditions, and the
other 6 women did not have any of these three condi-
tions by the time of our baseline telephone interview.
We excluded three women with incomplete question-
naire data who were alive at the end of the follow-up
period. Therefore, 371 women were eligible for survival
analysis.
We conducted a follow-up telephone interview in
2002-2004 to collect additional SF-36 QOL information
2-5 years after the initial collection of herbal remedy
and QOL information. Of 374 case patients participating
in the baseline telephone interview, 26 were known to
have died when we began the follow-up interview. Of
the remaining 348 women, 17 women were not located
(4.9%); 26 subjects preferred not to participate (7.5%);
and 3 women were too ill to participate (0.9%). Three
hundred two women were interviewed. After excluding
the same three women with incomplete questionnaire
data, 299 women remained for analysis of the associa-
tion between herbal remedy use and QOL. The recruit-
ment results are combined and shown in Figure 1.
Data collection
In the parent study, we obtained data on summary stage
at breast cancer diagnosis from the LA-CSP. The baseline
telephone interview for herbal remedy use (1999-2000)
obtained information on herbal remedy use, SF-36 QOL
measures, psychosocial functioning, cancer-related fac-
tors including recurrences, breast-cancer surgeries and
reconstructive history, treatments received for breast
cancer, and comorbidities. We also updated demographic
information and information on lifestyle practices after
breast cancer diagnosis.
Women were given a list of herbal remedies and asked
whether they had used any of the listed remedies within
the past six months. The remedies listed were bee pol-
len, licorice root, black cohosh, mother wort, blue
cohosh, nux vomica, chaste berries, progesterone topical
(vitex agnus cactii), progesterone cream (wild Mexican
yam), chickweed tincture, pulsatilla, dong quai (tong
Kwai), royal jelly, echinacea, sage tea, evening primrose
oil, sarsaparilla, false unicorn, sepia, garlic, St. John’s
Wort, ginko biloba, valerian a ,g i n s e n g ,w i l dy a mr o o t ,
herbal tea used as a remedy, shark cartilage, or lachesis.
Use of any of the herbal remedies qualified a woman as
an herbal remedy user.
The follow-up telephone interview (2002-2004) again
measured SF-36 QOL and psychosocial functioning;
updated demographic information and lifestyle practices
and cancer-related and treatment-related factors includ-
ing additional surgeries. Subjects were mailed a list of
scale responses to the QOL and psychosocial instruments
Figure 1 Participant recruitment.
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interview process.
Health-related QOL was assessed using the SF-36
questionnaire at each telephone interview. This widely
used self-report measure contains 36 items in eight sub-
scales (physical functioning, bodily pain, role limitations
due to physical functioning, role limitations due to emo-
tional problems, emotional well-being, social function-
ing, energy/fatigue, and general health perceptions)
[22,23]. Each subscale represents a combined score
(range: 0-100) derived from questions related to a parti-
cular health concept. The SF-36 has been shown to be
both valid and reliable [22]. Mental component scale
(MCS) and physical component scale (PCS) summary
scores account for 81.5% of the reliable variance in the
eight SF-36 scales and are therefore useful in providing
a summarized interpretation of QOL [24,25]. In addi-
tion, these two scales have been scored in reference to a
normal population (the 1998 general U.S. population,
standard form) [26].
All participants who had previously signed an
informed consent as part of their recruitment for the
parent study gave a verbal informed consent prior to
the conduct of each telephone interview. The study was
approved by the Institutional Review Boards at the Uni-
versity of Southern California and the City of Hope.
Statistical analysis
We compared demographic characteristics between her-
bal remedy users and non-users using Pearson chi-
square tests for differences in frequency distributions.
Survival time was calculated as the time from the col-
lection of herbal use at baseline telephone interview to
the first of the following events: date of death or the
end of follow-up on December 31, 2007. For breast can-
cer specific survival, we censored women who died from
other causes on their dates of death. We used the
Kaplan-Meier method to calculate survival rates and
applied the log-rank test to test for any difference in
survival between herbal remedy users and non-users.
Multivariable Cox proportional hazards regression
models were fit separately for all-cause and breast can-
cer mortality to assess the hazard rate ratios of mortality
associated with a woman’s herbal remedy use within the
6 months prior to the baseline telephone interview.
Hazard rate ratios, presented as relative risks (RRs) with
95% confidence intervals (CIs) were estimated using age
in days at the start and end of follow-up to define a
woman’s participation time in the study.
Among women who participated in the follow-up tele-
phone interview, we used t-tests to compare the QOL
summary scale measures between herbal remedy users
and non-users at baseline and follow-up surveys, respec-
tively. We further applied multivariable linear regression
models to compare average SF-36 health summary scale
change scores (change score = follow-up score - baseline
score) between herbal remedy users and non-users.
All multivariable models adjusted for the following
factors, selected a priori, as potential confounders: ethni-
city (non-Hispanic origin white, Hispanic origin white),
age at diagnosis (< 35, 35-38, 39-40 years), stage of can-
cer at diagnosis (in situ, localized invasive, non-localized
invasive), type of non-surgical treatment for initial breast
cancer (no treatment, only chemotherapy, only radiation
therapy, only hormonal therapy, any combinations of
these therapies), type of surgery (lumpectomy, mastect-
omy), post-diagnosis cancer-related conditions (none, 1,
≥ 2 cancer conditions that included lymphedema, con-
tralateral breast cancer, recurrence of the primary breast
cancer, diagnosis of cancer at another site, and history
of any breast cancer metastasis), comorbidities within
six months of baseline interview (none, 1, ≥ 2 including
cardiovascular diseases [defined as high blood pressure
requiring medication, angina, having had an angiogram,
high cholesterol, clotting disorder, or stroke], respiratory
problems [asthma or allergy disorder affecting breath-
ing], inflammatory conditions [arthritis, gall bladder dis-
ease, diabetes], musculoskeletal conditions [osteoporosis,
recent fracture], nervous system disorders [migraines,
hearing loss, psychiatric problem], drug abuse [excessive
use of alcohol or problem with prescription or street
drug use or dependency]), interval between diagnosis
and initial interview (10-11, 12-13, 14-16 years), and
annual income ($30,000, $30,001-60,000, $60,001-
100,000, > $100,000) at baseline interview. In addition,
when comparing average SF-36 health summary scale
change scores between herbal remedy users and non-
users, multivariable linear regression models were
adjusted for the SF-36 scores at baseline.
Our analysis of mortality had limited statistical power.
In estimating what we could expect to observe with 44
deaths during follow-up and a prevalence of 58.5% of
participants who had used herbal remedies, we could
detect a 60% or greater decrease in risk (RR = 0.4) or a
180% or greater increase in risk (RR = 2.8) for overall
mortality with 80% statistical power given a 2-sided
hypothesis test with a 5% level of statistical significance
[27].
Two-sided P- v a l u e so f0 . 0 5o rl e s sw e r ec o n s i d e r e d
statistically significant. We did not adjust P values for
multiple comparisons as these analyses were considered
as exploratory [28]. All analyses were performed using
SAS version 9.2 (SAS Institute, Cary, NC).
Results
Demographic characteristics
Of 371 breast cancer patients, 217 (58.5%) reported hav-
ing used herbal remedies within six months of baseline
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herbal remedies were echinacea (n = 107, 49%), herbal
teas as a remedy (n = 77, 35%), and ginko biloba (n =
70, 32%), which together accounted for 77% (n = 166)
of herbal remedy users. Compared to the non-users of
herbal remedies, the users were more likely to have
comorbidities and were less likely to have high income,
but were similar to non-users on other factors (Table 2).
Herbal remedy use and survival
Participants in the cohort were followed for an average of
7.8 years following their baseline telephone interview.
During the follow-up, 44 women died, including 33 who
died from breast cancer. The Kaplan-Meier survival
curve showed that both overall survival and breast cancer
survival of CAM users appeared to be poorer than that of
non-CAM users, but the differences were not statistically
significant (overall survival: P = 0.16, Figure 2; breast
cancer survival: P = 0.08, figure similar to that for overall
survival and not shown).
Overall herbal remedy use appeared to be associated
with increased risks for all-cause mortality (RR = 1.28,
95% CI = 0.62-2.64), and breast cancer mortality
(RR = 1.78, 95% CI = 0.72-4.40) (Table 3). Further, a
Table 1 Herbal remedy use
a among 371 participants
Number of participants
(%)
Used herbal remedy(ies) 217 (58.5)
Among herbal remedy users
Echinacea 107 (49.3)
Herbal tea used as a remedy 77 (35.5)
Ginko biloba 70 (32.3)
Ginseng 48 (22.1)
St. John’s Wort 47 (21.7)
Garlic 39 (18.0)
Evening primrose oil 26 (12.0)
Dong quai (tong Kwai) 18 (8.3)
Black cohosh 16 (7.4)
Bee Pollen 15 (6.9)
Progesterone topical cream (wild Mexican
yam)
15 (6.9)
Valeriana 13 (6.0)
Wild yam root 10 (4.6)
Shark cartilage 9 (4.2)
Licorice root 9 (4.2)
Royal jelly 6 (2.8)
Chaste berries (vitex agnus cactii) 3 (1.4)
Chickweed tincture 2 (0.9)
Sage tea 3 (1.4)
Mother wort 1 (0.5)
Pulsatilla 1 (0.5)
Sepia 1 (0.5)
Sarsaparilla 0
Blue cohosh 0
False unicorn 0
Lachesis 0
Nux vomica 0
Others 35 (16.1)
awithin the past six months of the baseline telephone survey.
Table 2 Demographic characteristics of 371 participants
Herbal remedy use
No
(n = 154)
Yes
(n = 217)
P
value
a
Ethnicity 0.28
White 136 (40.6%) 199 (59.4%)
Hispanic/Latino 18 (50.0%) 18 (50.0%)
Age at diagnosis, years 0.40
< 35 37 (35.9%) 66 (64.1%)
35-38 69 (43.4%) 90 (56.6%)
39-40 48 (44.0%) 61 (56.0%)
Stage of cancer at diagnosis 0.14
In situ 22 (43.1%) 29 (56.9%)
Invasive local 94 (45.2%) 114 (54.8%)
Invasive non-local 38 (33.9%) 74 (66.1%)
Type of no-surgical treatment
No treatment 40 (45.5%) 48 (54.5%) 0.83
Chemotherapy only 26 (41.9%) 36 (58.1%)
Radiation therapy only 26 (44.1%) 33 (55.9%)
Hormonal therapy only 5 (35.7%) 9 (64.3%)
Any combination of therapies 57 (38.5%) 91 (61.5%)
Type of surgery 0.07
Lumpectomy 39 (34.5%) 74 (65.5%)
Mastectomy 115 (44.6%) 143 (55.4%)
Post-diagnosis cancer-related
conditions
b
0.26
None 98 (44.1%) 124 (55.9%)
1 cancer condition 35 (34.7%) 66 (65.3%)
≥ 2 cancer conditions 21 (43.8%) 27 (56.2%)
Comorbidities
c
None 39 (62.9%) 23 (37.1%) 0.0005
1 medication 47 (40.9%) 68 (59.1%)
≥ 2 medications 68 (35.1%) 126 (64.9%)
Interval between diagnosis and
baseline interview, years
0.62
10-11 42 (37.8%) 69 (62.2%)
12-13 55 (42.3%) 75 (57.7%)
≥ 14 57 (43.9%) 73 (56.1%)
Yearly income at baseline 0.02
≤ $30,000 18 (41.9%) 25 (58.1%)
$30,001-$60,000 39 (38.2%) 63 (61.8%)
$60,001-$100,000 32 (32.0%) 68 (68.0%)
> $100,000 65 (51.6%) 61 (48.4%)
aP value ascertained from Pearson’s chi-square test.
bPost-diagnosis cancer-related conditions: breast cancer recurrence or
metastasis, contralateral breast cancer, cancer at another site, lymphedema.
cComorbidities: cardiovascular diseases, respiratory problems, inflammatory
conditions, musculoskeletal conditions, nervous system disorders, drug abuse.
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Table 3 Adjusted
a relative risk of mortality associated with herbal remedy use among 371 participants, 1999-2007
All-cause mortality Breast cancer mortality
No. Subjects No. deaths Adjusted
a RR (95% CI) No. Subjects No. deaths Adjusted
a RR (95% CI)
Overall herbal remedy use
No 154 14 1.00 154 9 1.00
Yes 217 30 1.28 (0.62-2.64) 217 24 1.78 (0.72-4.40)
By type
Echinacea use
No 264 30 1.00 264 20 1.00
Yes 107 14 1.14 (0.55-2.35) 107 13 1.85 (0.80-4.29)
Herbal tea used as a remedy
No 294 31 1.00 294 22 1.00
Yes 77 13 1.61 (0.78-3.29) 66 11 1.90 (0.83-4.35)
Ginko biloba use
No 301 37 1.00 301 27 1.00
Yes 70 7 0.80 (0.34-1.89) 70 6 0.99 (0.38-2.60)
aAdjusted for ethnicity, age at diagnosis, stage of cancer at diagnosis, type of non-surgical treatment, type of surgery, post-diagnosis cancer-related conditions,
comorbidities, interval between diagnosis and baseline interview, annual income at baseline interview.
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cancer mortality was associated with echinacea use (RR
= 1.85, 95% CI = 0.80-4.29) and herbal tea used as a
remedy (RR = 1.90, 95% CI = 0.83-4.35), but was not
associated with ginko biloba use (RR = 0.99, 95% CI =
0.38-2.60).
Herbal remedy use and QOL
Univariate analyses showed that at the baseline interview
assessment, women reporting herbal remedy use had a
lower mean SF-36 mental component summary score (P
= 0.05) than women who reported no herbal remedy
use, but their mean SF-36 physical component scale
summary score was not statistically different from that
of non-users (P = 0.37). However, 2-5 years after herbal
remedy use information was collected, herbal remedy
users’ SF-36 mental and physical component summary
scores were lower than those for non-users (all P < 0.05,
results not shown).
Multivariable analyses of change scores between base-
line and follow-up survey showed that both herbal
remedy users’ and non-users’ mental component sum-
mary scores on the SF-36 increased similarly from base-
line to follow-up (1.5 vs. 3.2, P = 0.16), but herbal
remedy users’ physical component summary scores
decreased more than those of non-users (-5.7 vs. -3.2,
P = 0.02, Table 4). Furthermore, herbal remedy users
had a greater decline in the energy/fatigue (-7.3 vs. -1.8
vs., P = 0.02), physical role limitations (-13.7 vs. -3.9,
P = 0.02), bodily pain (-11.4 vs. -3.4, P = 0.003), and
general health (-6.4 vs. -2.1, P = 0.04) subscales and a
smaller increase in the social functioning subscale (3.5
vs. 9.8, P = 0.04). No statistically significant difference in
change scores was observed for the most commonly
used specific types of herbal remedies (all P > 0.05).
Discussion
Herbal remedy use was associated with non-statistically
significant increases in the risks for all-cause and breast
cancer mortality. Both herbal remedy users’ and non-
users’ mental component summary scores on the SF-36
increased similarly from the first survey to the second
survey, but herbal remedy users’ physical component
summary scores decreased more than those of non-
users.
This study has several important limitations which
may affect the results we observed. First, although our
results were obtained from a prospective study of young
breast cancer patients who had survived more than 10
years, 276 (37%) breast cancer patients had died by the
time we initiated this study, so that participants were
more likely to be a select group of healthy women who
were long-term survivors. Thus, our findings may not
be generalizable to all breast cancer patients, but they
do provide important information regarding long-term
survivors of breast cancer who were diagnosed at a
young age. Second, herbal remedy use, as measured in
our study, represents use during a six month time per-
iod beginning, on average, 12.5 years after breast cancer
diagnosis. We did not collect information regarding the
timing of initiation of herbal remedy use, duration or
frequency of use or reasons for use. Herbal teas were
Table 4 Adjusted
a mean differences
b in SF-36 summary and subscale scores between two interviews among 299
participants
Overall herbal remedy use Echinacea use Herbal teas Ginko biloba use
No.
(n = 120)
Yes
(n = 179)
P
value
No.
(n = 210)
Yes
(n = 89)
P
value
No
(n = 239)
Yes
(n = 60)
P
value
No
(n = 236)
Yes
(n = 63)
P
value
Summary scale
PCS (physical health) -3.2 -5.7 0.02 -4.6 -5.4 0.46 -4.6 -5.5 0.47 -5.0 -4.4 0.64
MCS (mental health) 3.2 1.5 0.16 1.9 2.7 0.54 2.4 1.4 0.49 1.8 2.9 0.45
Subscale
Energy/fatigue -1.8 -7.3 0.02 -5.2 -5.6 0.87 -5.1 -5.8 0.82 -5.1 -5.9 0.79
Physical functioning -9.3 -11.8 0.21 -10.6 -11.4 0.71 -11.2 -9.9 0.62 -11.3 -9.7 0.50
Role limitations,
physical
-3.9 -13.7 0.02 -10.1 -9.8 0.96 -8.5 -14.1 0.30 -11.0 -7.3 0.47
Emotional well-being 0.5 -0.5 0.58 -0.5 1.0 0.45 0.2 -1.2 0.54 -0.7 1.5 0.32
Role limitations,
emotional
4.7 -1.6 0.10 0.7 0.7 1.0 1.2 -0.6 0.70 -0.7 4.7 0.23
Social functioning 9.8 3.5 0.04 5.3 7.2 0.56 7.8 0.7 0.06 5.2 7.4 0.54
Bodily pain -3.4 -11.4 0.003 -7.5 -11.2 0.19 -7.3 -11.4 0.21 -9.0 -6.8 0.49
General health -2.1 -6.4 0.04 -4.5 -5.8 0.54 -3.6 -7.7 0.12 -5.4 -2.9 0.29
aAdjusted for ethnicity, age at diagnosis, stage of cancer at diagnosis, type of non-surgical treatments, type of surgery, post-diagnosis cancer-related conditions,
comorbidities, interval between diagnosis and first interview, yearly income at baseline interview, and the corresponding QOL measures at baseline interview.
bDifference = QOL measure at follow-up - QOL measure at baseline interview.
Ma et al. BMC Cancer 2011, 11:222
http://www.biomedcentral.com/1471-2407/11/222
Page 7 of 10commonly used herbal remedies among our study popu-
lation, but we did not collect the components of herbal
teas or brand of herbal teas or whether any additives
had been added to herbal teas to alter color or taste.
Third, we relied on self reported information on herbal
remedy use. Errors in reporting use of herbal prepara-
tions are possible. However, we worded questions care-
fully, mailed scales and questionnaire items in advance
of the telephone interview to enhance comprehension
and consistency of reporting, and limited the questions
to recent herbal remedy usage (within the past six
months of interview). Fourth, among 33 women who
died from breast cancer during our follow-up for survi-
val, 27 had post-diagnosis cancer-related conditions
including two who had a contralateral breast cancer by
t h et i m eo fo u rb a s e l i n et e l e p hone interview. Unfortu-
nately, we were unable to collect this information
throughout the follow-up for survival. Therefore, we
cannot rule out the possibility that women might have
died of a new breast cancer rather than their first pri-
mary breast cancer. Fifth, due to the relatively small
number of participants, we only assessed the effects for
overall herbal remedy use and three commonly used
herbal remedies. We were unable to explore the effects
for those having a lower frequency of use among our
participants. In fact, even for overall herbal remedy use,
the small number of deaths led to insufficient statistical
power to detect small or moderate differences in mortal-
ity risk between herbal remedy users and non-users.
Due to the same limitation, our main exposure variable,
herbal remedy use, grouped all types of herbal remedies.
The definition of herbal remedy use was therefore non-
specific. Finally, six of forty P values we reported here
for testing the roles of herbal remedies in quality of life
reached statistical significance (P ≤ 0.05); we did not
adjust for multiple comparisons as, with the relatively
small number of participants, these analyses were con-
sider as exploratory.
Our data show that herbal remedy use tended to be
associated with a poor survival among long-term breast
cancer survivors although the associations did not reach
statistical significance, due to the small number of
deaths and further deaths could alter the direction of
findings. Our findings are consistent with a Norwegian
study which followed 515 patients with a variety of can-
cers for up to 8 years and showed that CAM use was
associated with poorer survival; 79% of CAM users died
during follow-up compared with 65% of nonusers [10].
However, a second Norwegian study which followed 252
patients with heterogeneous cancers for up to 5 years
did not find any association between CAM use and
mortality [9].
Our data also showed that herbal remedy users’ physi-
cal component summary scores decreased more than
those of non-users between the first and second surveys.
Most previous studies that have evaluated CAM or her-
bal remedy use in relation to QOL were conducted
among patients within 5 years of initial diagnosis
[11-14]; however, one study evaluated CAM use in a
large sample of women who were diagnosed from 5 to
10 years earlier [16] and our prior report for this study
population assessed the association between CAM use
and QOL concurrently among 10-16 year survivors [20].
Among these studies, one found that CAM users (either
all CAM or herbal CAM) had poorer physical and men-
tal health function than non-users [11]; three showed
poorer mental health function among CAM users com-
pared to non-users [12,16,20], but not physical health
function. A study conducted among Chinese breast can-
cer survivors found no association between any Chinese
herbal medication use and perceived overall QOL [13].
However, in all but one study [12], the information on
health-related QOL was collected at the same point in
time as CAM use was collected. The study [12], which
assessed QOL after CAM use, was able to determine if
CAM use had been initiated prior to breast cancer treat-
ment or subsequent to it, but covered only the 12
month period following initial diagnosis.
Reasons are unclear for our observation that herbal
remedy use was associated with a poorer survival or
greater decline in physical health summary scores
between our two surveys. A recent published Norwegian
study investigating CAM use in 735 cancer patients who
had survived 5 years or more after breast cancer diagno-
sis, found CAM use initiated after diagnosis was asso-
ciated with a poor prognosis suggesting that CAM
might be used by those with less hope of a cure by con-
ventional therapy [29]. Although no published data
directly indicated that CAM use is associated with a
lower score of QOL measures in the general population,
previous data have shown that substantial amount of
CAM use can be attributed to poorer health or the
treatment of existing chronic health conditions
[1,30-32]. Based on a national telephone interview sur-
vey conducted in the United States in 1997, 42% of all
alternative therapies were used exclusively to treat exist-
ing illness [1]. Among breast cancer patients in one
study, a variety of symptoms (treatment side effects as
well as other health and cancer-related problems) have
been positively related to the initiation of CAM use
[12]. We found that herbal remedy users in our study
were more likely to have comorbidities at the baseline
interview assessment. The poorer survival and greater
decrease in physical component summary scores among
herbal remedy users may have resulted from poorer
health motivating the use of remedies to alleviate symp-
toms although we controlled for comorbidities when
comparing herbal remedy users and non-users. The
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component score between herbal remedy users and
non-users remained when analyses were restricted to
women without any comorbidities considered in our
study.
We also considered that the lower physical QOL
scores of the herbal remedy users might result from
some of the users opting out of conventional therapy
for breast cancer. Therefore, we adjusted for types of
initial treatments (both surgical and non-surgical) in our
analyses. Based on previous studies, approximately 5-
12% of cancer patients may abandon appropriate ther-
apy and pursue alternative treatments [33,34]; yet in
most cases, alternative medicine is used to complement
rather than replace conventional therapy [12,33,34].
It is possible that herbal remedy use could have inter-
fered with chemotherapy treatment by inhibiting some
enzymes in the cytochrome P450 (CYP) family, such as
CYP1A2, CYP2C9, CYP2D6, CYP2E1, and CYP3A4
[35,36] if this use was initiated soon after diagnosis.
This might explain the poorer survival and greater
decline in physical health summary scores among herbal
remedy users. However, as our participants were, on
average, 13-year survivors, any potential interaction
between chemotherapy treatment and concurrent herbal
remedy use would not be expected to persist. Therefore,
the associations that we observed in the current data
need to be verified in the future studies with a larger
sample size.
Conclusions
Our data provide some evidence that herbal remedy use
is associated with a poorer survival and a poorer physi-
cal component score for health-related QOL among
long-term (> 10 years) breast cancer survivors. These
conclusions are based on the exploratory data from a
prospective study using two-sided statistical tests with
no correction for multiple testing and are limited by the
few deaths for the survival assessment and the lack of
information regarding the timing of initiation of herbal
remedy use or duration or frequency of, or reasons for
herbal remedy use. The potential roles for herbal reme-
dies in breast cancer patients’ survival and QOL merit
further exploration.
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